Releases older than 6 months are archived on this page. Current press releases can be found on the press releases page.
Releases older than 6 months are archived on this page. Current press releases can be found on the press releases page.
DECEMBER 17, 1996
MONSANTO'S SEARLE UNIT ENTERS STRATEGIC ALLIANCE WITH ETHICAL HOLDINGS FOR HORMONE-REPLACEMENT-THERAPY PATCH PRODUCTS
hrtrel.html [html file]
HRTREL.TXT [4 k, text file]
NOVEMBER 6, 1996
FIRST COMPARISON OF POPULAR ENDOMETRIOSIS DRUGS SHOWS ONE IS EASIER ON BONES
— Results Encouraging for Research on Longer-Term Drug Intervention —
OCTOBER 14, 1996
CONSUMERS SHOULD "SEE THEIR DOCS WHEN THEY CHANGE THEIR CLOCKS" SUGGESTS NEW GALLUP RESEARCH
OCTOBER 8, 1996
POPULAR DRUGS FOR GI PROBLEMS MAY INCREASE RISK OF SERIOUS COMPLICATIONS IN ARTHRITIS PATIENTS
SEPTEMBER 30, 1996
GOING OVER 55 ON THE INFORMATION SUPERHIGHWAY:
SENIORS WITH ARTHRITIS NAVIGATE THE INTERNET TO MANAGE THEIR HEALTH
JULY 22, 1996
ANTACIDS AND ACID BLOCKERS FOUND TO BE INEFFECTIVE IN PREVENTING GASTROINTESTINAL DAMAGE IN ARTHRITIS PATIENTS
JULY 7, 1996
G. D. SEARLE & COMPANY ANNOUNCES INTENT TO MAKE PATENT ESTATE FOR PROTEASE INHIBITOR PROGRAM AVAILABLE FOR COMMERCIALIZATION
JUNE 26, 1996
POSITIVE TRIAL RESULTS ANNOUNCED FOR ARTHRITIS/PAIN TREATMENT
JUNE 3, 1996
SEARLE LAUNCHES COVERA-HS™ ON JUNE 3
World's First Chronotherapeutic for Hypertension and Angina Is Now Available
MAY 21, 1996
COCENSYS AND SEARLE TO COLLABORATE ON DEVELOPMENT/MARKETING OF NOVEL INSOMNIA TREATMENT
MAY 15, 1996
SEARLE READIES COVERA-HS™ FOR JUNE 3 LAUNCH
World's First Chronotherapeutic for Hypertension and Angina Will Soon Be Available to Physicians
MAY 15, 1996
NEW GALLUP SURVEY SHOWS PHYSICIANS STRESS CHRONOTHERAPEUTICS' ROLE IN HYPERTENSION AND ANGINA TREATMENT
MAY 5, 1996
NEW RESEARCH MAY LEAD TO BREAKTHROUGH IN ARTHRITIS CARE
FEBRUARY 27, 1996
COVERA-HS -- SEARLE'S NEW ONCE-DAILY ANTIHYPERTENSIVE/ANTI-ANGINAL PRODUCT WITH NOVEL DELIVERY SYSTEM -- CLEARED BY FDA FOR MARKETING
JANUARY 30, 1996
SEARLE ANNOUNCES PURCHASE OF REMAINING SHARES IN BRAZILIAN JOINT VENTURE
JANUARY 29, 1996
APPROVABLE LETTER RECEIVED FOR COVERA-HS
JANUARY 25, 1996
SEARLE AGREES WITH FDA CARDIO-RENAL ADVISORY COMMITTEE THAT ALL CALCIUM CHANNEL BLOCKERS ARE NOT ALIKE
JANUARY 17, 1996
SEARLE AND HYBRIDON SIGN LETTER OF INTENT
JANUARY 15, 1996
FDA APPROVAL SOUGHT FOR NEW NSAID
DECEMBER 5, 1995
NEW GALLUP FINDINGS: AMERICANS KNOW THEY'RE SLEEP-DEPRIVED, BUT DO NOT SEEK EFFECTIVE RELIEF
DECEMBER 5, 1995
WORK DEMANDS AND STRESS MAY BE ROBBING AMERICANS OF SLEEP, NEW GALLUP STUDY REVEALS
NOVEMBER 13, 1995
MAJOR NEW LONG-TERM TRIAL USING CALCIUM CHANNEL BLOCKER WITH NOVEL DRUG DELIVERY SYSTEM ANNOUNCED AT AMERICAN HEART ASSOCIATION MEETING
OCTOBER 23, 1995
STUDIES RAISE QUESTIONS ABOUT ANTACID USE
OCTOBER 12, 1996
FDA COMMITTEE RECOMMENDS CHANGES IN NSAID LABELING
AUGUST 15, 1995
STUDY REVEALS WHICH NSAID USERS ARE MOST AT RISK OF SERIOUS GI DAMAGE
JULY 28, 1995
SEARLE ANNOUNCES AGREEMENT WITH SANKYO COMPANY, LTD. TO CO-DEVELOP AND CO-MARKET NOVEL CLOT-PREVENTING DRUG
JULY 26, 1995
MONSANTO'S SEARLE UNIT REACHES DEFINITIVE AGREEMENT TO ACQUIRE SYNTEX WOMEN'S HEALTH CARE PRODUCT LINES
